MARKET

ALPMF

ALPMF

Astellas Pharma
OTCPK
16.05
NaN%
Closed 09:30 02/13 EST
OPEN
--
PREV CLOSE
14.90
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
67.86
52 WEEK LOW
10.78
MARKET CAP
28.75B
P/E (TTM)
13.97
1D
5D
1M
3M
1Y
5Y
1D
Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus
TipRanks · 2d ago
Weekly Report: what happened at ALPMF last week (0202-0206)?
Weekly Report · 5d ago
Astellas-Backed Bladder Cancer Trial Nears Key Data Moment After Study Completion
TipRanks · 02/05 16:31
Goldman Sachs Remains a Buy on Astellas Pharma (ALPMF)
TipRanks · 02/05 10:25
Astellas Pharma (ALPMF) Gets a Hold from Morgan Stanley
TipRanks · 02/05 10:25
Bernstein Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)
TipRanks · 02/04 12:57
Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold
TipRanks · 02/04 12:56
Astellas Pharma ADR GAAP EPS of ¥185.20, revenue of ¥1601.32B; updates full-year forecast
Seeking Alpha · 02/04 07:09
More
About ALPMF
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Webull offers Astellas Pharma Inc stock information, including OTCPK: ALPMF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPMF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALPMF stock methods without spending real money on the virtual paper trading platform.